Second Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer Patients

NCT05833919 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
122
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Consorzio Oncotech